名稱 | EGFR L858R-T790M-C797S/BaF3 |
型號 | CBP73049 |
報(bào)價(jià) | ![]() |
特點(diǎn) | EGFR L858R-T790M-C797S/BaF3,母細(xì)胞:BaF3,凍存條件:90% FBS+10% DMSO |
產(chǎn)品搜索
相關(guān)文章
- 甲基丙二酸血癥(MMA)標(biāo)準(zhǔn)品上新
- 【產(chǎn)品推介】TERT診斷標(biāo)準(zhǔn)品
- 你知道ATCC細(xì)胞如何解凍嗎?
- 有關(guān)腫瘤細(xì)胞的基因突變研究講解
- BCMA靶點(diǎn)藥物細(xì)胞篩選模型
- CD47/PD-(L)1 雙靶點(diǎn)細(xì)胞篩選模型簡介
- 從“腫瘤免疫療法”發(fā)展,看“單抗、CAR-T”任重而道遠(yuǎn)!
- 子宮內(nèi)膜癌精準(zhǔn)分子分型標(biāo)準(zhǔn)品,助力POLE基因檢測
- 耐藥ATCC細(xì)胞株如何構(gòu)建看完就會知道
- 腫瘤細(xì)胞的信息系統(tǒng)的改變特征大揭秘
聯(lián)系我們
電話:4008750250
號碼:
手機(jī):18066071954
地址:南京市棲霞區(qū)緯地路9號
Email: zhangxiangwen@cobioer.com
產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > kinase激酶細(xì)胞株 > CBP73049EGFR L858R-T790M-C797S/BaF3

- 詳細(xì)內(nèi)容
CBP73049 | |
I. Introduction | |
Cell Line Name: | EGFR L858R-T790M-C797S/BaF3 |
Host Cell: | Ba/F3 |
Stability: | 16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
Application: | Anti-proliferation assay and PD assay |
Freeze Medium: | 90% FBS+10% DMSO |
Complete Culture Medium: | RPMI-1640+10%FBS |
Mycoplasma Status: | Negative |
II.Background | |
EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section). In ligand-activated cancers, Cetuximab appears to be more effective than tyrosine-kinase inhibitors. | |
III. Representative Data | |
1. WB of EGFR-L858R/T790M/C797S expression | |
Figure 1. WB of EGFR Expression Lane 1: Negative control Lane 2: EGFR-WT Lane 3: EGFR-L858R/T790M Lane 4: EGFR-L858R/T790M/C797S | |
2. Sanger sequencing | |
Figure 2. Sanger Sequencing of EGFR-L858R/T790M/C797S | |
3. Anti-proliferation assay | |
Figure 3. Anti-proliferation assay of three reference compounds on the EGFR L858R-T790M-C797S/BaF3 Stable Cell Line |